These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33380880)

  • 41. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities.
    Stamatopoulos K; Pavlova S; Al-Sawaf O; Chatzikonstantinou T; Karamanidou C; Gaidano G; Cymbalista F; Kater AP; Rawstron A; Scarfò L; Ghia P; Rosenquist R
    Hemasphere; 2024 Jul; 8(7):e113. PubMed ID: 39035106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Analysis of infection in B-cell lymphoma patients treated with BTK inhibitors].
    Wang CM; Liu H; Li LJ; Song J; Wang HQ; Wu YH; Guan J; Xing LM; Wang GJ; Liu H; Qu W; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):582-586. PubMed ID: 37749040
    [No Abstract]   [Full Text] [Related]  

  • 43. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.
    Nixon S; Duquette D; Doucette S; Larouche JF
    Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia.
    Kulumani Mahadevan LS; Ozdemirli M
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34580127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
    Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH
    Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    Cherng HJ; Jain N
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):725-738. PubMed ID: 34174983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
    Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
    Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
    Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
    Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
    Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
    Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.